> Back to EJC

Recent editions

  • June 2014
    Hans Clevers on important research into stem cells in normal gut tissue.
  • May 2014
    Carolyn Taylor and Paul McGale find evidence to clarify guidelines for radiotherapy after mastectomy.
  • April 2014
    Richard Sullivan and Ajay Aggarwal on how physicians can tackle the issue of affordability in cancer care.
  • March 2014
    The 1st EORTC Cancer Survivorship Summit addressed the practical problems faced by cancer patients.
  • February 2014
    Charles Swanton on a study that maps genetic changes in cancers over time.
  • January 2014
    Presidents of various cancer societies make predictions for the coming year.
  • December 2013
    Precision diagnostics have great potential, but changes are needed to make them more available.
  • November 2013
    Highlights of the European Cancer Congress - cancer society presidents give their view.
  • October 2013
    Richard Schilsky on the changes needed as personalised medicine enters the clinic.
  • September 2013
    A new advance in immunotherapy is discussed by Jean-Charles Soria and Caroline Robert.
  • July/August 2013
    EORTC President Roger Stupp on challenges for clinical trials research.

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

 

EJC News Focus – April 2013

Loading EJC News Focus video

What impact will an ageing population have in cancer?

The increasing burden of cancer in an ageing population is widely accepted, but more detailed discussion of the implications for patients, oncologists and healthcare systems is sometimes lacking. Elderly patients may of course need specific treatment approaches, but experts are calling for a more wide-ranging debate on measures that need to be put in place now to meet the needs of an ageing population. In this month's EJC News Focus, Richard Marais, David Cameron, Mary O'Brien, Roger Stupp, Manuela Schmidinger and Jan Willem Coebergh tell Helen Saul that it's time to re-look at screening and treatment guidelines, at survivorship issues, and the structures that will be needed to deal with co-morbidity.